ZRE Stock Chart & Stats
€10.97
-€0.04(-0.36%)
At close: 4:00 PM EDT
€10.97
-€0.04(-0.36%)
Day’s Range― - ―
52-Week Range€4.31 - €11.90
Previous CloseN/A
Volume2.00
Average Volume (3M)2.47K
Market Cap
€552.12M
Enterprise Value€604.15
Total Cash (Recent Filing)€89.80M
Total Debt (Recent Filing)€265.68M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 18, 2027EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding54,000,000
10 Day Avg. Volume1,017
30 Day Avg. Volume2,471
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.04Price Target Upside9.78% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.81
Revenue Forecast (FY)€1.33B
Bulls Say, Bears Say
Bulls Say
Accelerating Prescription Growth And Customer RetentionStrong prescription growth and materially better retention indicate rising adoption of e-prescriptions and improving customer lifetime value. These trends can deepen DocMorris’s position in digital pharmacy while supporting more recurring revenue.
Scalable Digital Healthcare Platform GrowthRapid Digital Services and TeleClinic expansion broadens DocMorris beyond product distribution into healthcare access and treatment support. The platform’s growth and improving TeleClinic EBITDA could create higher-margin, scalable revenue streams.
Structural Cost Improvement And Path To BreakevenRecurring AI-led savings, lower marketing costs and tighter guidance support a durable operating-leverage story. If execution continues, these initiatives can narrow losses, improve margins and reduce the funding burden as revenue expands.
Bears Say
Persistent Cash Burn And Rising Net DebtNegative operating cash flow and higher net debt limit financial flexibility while the company funds growth and transformation. Delayed free-cash-flow breakeven increases dependence on liquidity and external funding if improvement takes longer.
Loss-making Operations And Weak ProfitabilityPersistent operating and net losses show that scale has not yet translated into sustainable profitability. Volatile earnings and deteriorating gross profit make the recovery plan more execution-sensitive and reduce resilience against cost or pricing pressure.
Regulatory And Patient Co-payment PressureChanges to German reimbursement economics and higher patient co-payments could increase price sensitivity and pressure prescription demand or margins. Regulatory scrutiny of co-payment exemptions adds uncertainty to a strategically important market.
ZRE FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was €4.31 and its highest was €11.90 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is €552.12M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 18, 2027 which is in 202 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2026. The company reported -€1.177 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -0.63.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -€1.177 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in DE:ZRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
ZRE Stock 12 Month Forecast
Average Price Target
€12.04
▲(9.78% Upside)